Anzeige
Mehr »
Freitag, 20.03.2026 - Börsentäglich über 12.000 News
Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
24.02.Novo to cut GLP-1 drug prices; Palvella soars on study data
24.02.Novo, searching for a spark, spotlights new data for three-pronged obesity drug
24.02.Slate starts up with $130M and a headache drug from China
23.02.FDA fleshes out new roadmap for testing personalized therapies
23.02.Novo's next-gen obesity shot fails to match Lilly drug in head-to-head study
23.02.Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
23.02.Merck to split cancer, specialty drug businesses in leadership shakeup
23.02.All about cell therapy process characterization
23.02.Small and mighty: single-domain antibodies pack a biological punch
20.02.Grail's multi-cancer early detection test misses study goal
20.02.Supreme Court invalidates Trump tariffs based on emergency powers
20.02.Roche gets FDA decision date on closely watched breast cancer drug
20.02.Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
20.02.AI is slashing jobs across industries. Will pharma be next?
19.02.Altesa, run by former Trump official, raises $75M for well-traveled lung drug
19.02.FDA leaders say one pivotal trial, not two, should be 'default' for drug approvals
18.02.Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6
18.02.An Alzheimer's startup emerges with $175M in venture backing
18.02.Psychedelics stocks rise as Compass' psilocybin drug heads to FDA
18.02.FDA reverses course on Moderna's flu vaccine
18.02.FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
17.02.Compass, with Phase 3 hits, ready to take psilocybin to the FDA
17.02.Ocular claims a win with Phase 3 eye drug data even as shares sink
17.02.Selecting the optimal cell therapy manufacturing platform
17.02.How to evaluate prospective diagnostic laboratory partners for your patient support program